Mutational diversity and therapy response in breast cancer - a sequencing analysis in the neoadjuvant GeparSepto trial.

CONCLUSIONS: High genetic heterogeneity was observed in different BC subtypes. Our study shows that FFPE-based NGS can be used to identify markers of therapy resistance in clinical study cohorts. PIK3CA mutations could be a major mediator of therapy resistance in BC.
PMID: 30979740 [PubMed - as supplied by publisher]

Source: Clinical Cancer Research - April 11, 2019 Category: Cancer & Oncology Authors: Loibl S, Treue D, Budczies J, Weber K, Stenzinger A, Schmitt WD, Weichert W, Jank P, Furlanetto J, Klauschen F, Karn T, Pfarr N, von Minckwitz G, Möbs M, Jackisch C, Sers C, Scneeweiss A, Fasching PA, Schem C, Hummel M, van Mackelenbergh MT, Nekljudova V Tags: Clin Cancer Res Source Type: research